Compare iShares MSCI Australia ETF (EWA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs TransMedics Group Inc — how do they compare? iShares MSCI Australia ETF trades at $28.7 (market cap $1.17B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 2.3× iShares MSCI Australia ETF's market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and TransMedics Group Inc for 24 Days on average.
| EWA | TMDX | |
|---|---|---|
Market Cap | $1.17B | $2.74B |
Volume | 2,121,231 | 949,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $150.42 |
52-Week Low | $24.95 | $61.99 |
Typical Hold Time | 61 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.62, up 1.38% today, but faces a bearish technical outlook with all moving averages signaling sell. The ETF's fundamentals lack key valuation and profitability data, while recent news highlights institutional selling and Australian market pressures from inflation concerns. As a commodity-focused proxy, its performance is tied to global demand and raw material prices.
The outlook is mixed, with Seeking Alpha projecting over 20% upside to $34.83, but technical weakness and macroeconomic risks from oil-driven inflation pose headwinds. Investment opportunity hinges on commodity strength, yet volatility from geopolitical and rate uncertainties requires caution for stock investors.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
